These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 20587323)
1. [Preventive effect of entecavir on hepatitis B flare up in HBsAg(+) breast cancer patients receiving chemotherapy]. Ding PP; He G Zhonghua Gan Zang Bing Za Zhi; 2010 Jun; 18(6):472-3. PubMed ID: 20587323 [No Abstract] [Full Text] [Related]
2. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117 [TBL] [Abstract][Full Text] [Related]
3. Lamivudine therapy in HBsAg-carrying breast cancer patients undergoing chemotherapy: prophylactic or preemptive? Dai MS; Chao TY Breast Cancer Res Treat; 2005 Jul; 92(1):95-6. PubMed ID: 15980997 [No Abstract] [Full Text] [Related]
4. Seroconversion of HBsAg in HBeAg positive and HBeAg negative patients with chronic HBV treated with entecavir: a case series. d'Ettorre G; Barbarini G; Corti F; Gobber M; Pastecchia C; Ricci GL; Siciliano M; Annicchiarico BE; Vullo V Eur Rev Med Pharmacol Sci; 2010 Jun; 14(6):551-4. PubMed ID: 20712263 [TBL] [Abstract][Full Text] [Related]
5. Hepatitis B-associated acute liver failure: immediate treatment with entecavir inhibits hepatitis B virus replication and potentially its sequelae. Jochum C; Gieseler RK; Gawlista I; Fiedler A; Manka P; Saner FH; Roggendorf M; Gerken G; Canbay A Digestion; 2009; 80(4):235-40. PubMed ID: 19828954 [TBL] [Abstract][Full Text] [Related]
6. [Prevention of hepatitis B virus reactivation in B-cell lymphoma patients receiving chemotherapy with rituximab]. Mimura N; Kojima H; Tsujimura H; Ise M; Sakai C; Fukai K; Yokosuka O; Kumagai K Rinsho Ketsueki; 2010 Mar; 51(3):213-5. PubMed ID: 20379117 [TBL] [Abstract][Full Text] [Related]
7. Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients. Watanabe M; Shibuya A; Takada J; Tanaka Y; Okuwaki Y; Minamino T; Hidaka H; Nakazawa T; Koizumi W Eur J Intern Med; 2010 Aug; 21(4):333-7. PubMed ID: 20603047 [TBL] [Abstract][Full Text] [Related]
8. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. Yeo W; Chan PK; Hui P; Ho WM; Lam KC; Kwan WH; Zhong S; Johnson PJ J Med Virol; 2003 Aug; 70(4):553-61. PubMed ID: 12794717 [TBL] [Abstract][Full Text] [Related]
9. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma. Wu JM; Huang YH; Lee PC; Lin HC; Lee SD J Clin Gastroenterol; 2009; 43(5):496-8. PubMed ID: 19247200 [TBL] [Abstract][Full Text] [Related]
10. Entecavir as prophylaxis against hepatitis B virus reactivation following chemotherapy for lymphoma. Uchiyama M; Tamai Y; Ikeda T Int J Infect Dis; 2010 Mar; 14(3):e265-6. PubMed ID: 19665406 [No Abstract] [Full Text] [Related]
11. Optimal antiviral prophylaxis against hepatitis B reactivation in patients receiving rituximab-based chemotherapy for lymphoma. Abramson JS; Chung RT JAMA; 2014 Dec; 312(23):2505-7. PubMed ID: 25514300 [No Abstract] [Full Text] [Related]
12. Hepatitis B virus-related membranous nephropathy treated with entecavir. Ikee R; Ishioka K; Oka M; Maesato K; Moriya H; Hidaka S; Ohtake T; Kobayashi S Nephrology (Carlton); 2010 Mar; 15(2):266. PubMed ID: 20470290 [No Abstract] [Full Text] [Related]
13. Entecavir to treat severe acute hepatitis B. De Socio GV; Mercuri A; Di Candilo F; Baldelli F Scand J Infect Dis; 2009; 41(9):703-4. PubMed ID: 19544224 [No Abstract] [Full Text] [Related]
14. Treatment to prevent hepatitis B virus reactivation in patients with lymphoma receiving chemotherapy. Baang J JAMA; 2015 Mar 24-31; 313(12):1269-70. PubMed ID: 25803354 [No Abstract] [Full Text] [Related]
15. [Five years trial of entecavir for chronic hepatitis B patients failed with lamivudine therapy in the Chongqing area]. LI H; WANG ZY; ZHANG DZ; SHI XF; ZHOU Z; REN H Zhonghua Gan Zang Bing Za Zhi; 2009 May; 17(5):338-41. PubMed ID: 19497197 [TBL] [Abstract][Full Text] [Related]
16. Treatment to prevent hepatitis B virus reactivation in patients with lymphoma receiving chemotherapy--reply. Lin T; Huang H; Li X JAMA; 2015 Mar 24-31; 313(12):1270. PubMed ID: 25803356 [No Abstract] [Full Text] [Related]
17. [New advances in the treatment of chronic hepatitis B: position of entecavir]. Olaso V Rev Esp Quimioter; 2007 Sep; 20(3):259-60. PubMed ID: 18080023 [No Abstract] [Full Text] [Related]
18. [Nucleos(t)ides as prophylaxis for the reactivation of hepatitis B virus in immunosuppressed patients]. Fan LY; Zhou Z; Zhong S; Ling N; Wang ZY; Shi XF; Zhang DZ; Ren H Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):429-33. PubMed ID: 19567021 [TBL] [Abstract][Full Text] [Related]
19. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Dai MS; Wu PF; Shyu RY; Lu JJ; Chao TY Liver Int; 2004 Dec; 24(6):540-6. PubMed ID: 15566502 [TBL] [Abstract][Full Text] [Related]
20. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. Lai CL; Shouval D; Lok AS; Chang TT; Cheinquer H; Goodman Z; DeHertogh D; Wilber R; Zink RC; Cross A; Colonno R; Fernandes L; N Engl J Med; 2006 Mar; 354(10):1011-20. PubMed ID: 16525138 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]